Pharma Mar, S.A.

Pharma Mar, S.A. is a Spanish biopharmaceutical company headquartered in Colmenar Viejo, Madrid, specializing in the research, development, manufacturing, and commercialization of antitumor drugs derived from marine organisms. Founded in 1986 as a subsidiary of Zeltia, it pioneered the first entirely Spanish-developed cancer drug, trabectedin (Yondelis), approved by the European Medicines Agency and FDA for treating advanced soft-tissue sarcoma and ovarian cancer. The company focuses on oncology, harnessing marine biodiversity's unique antitumor properties, and has expanded into gene silencing therapies through its subsidiary Sylentis using RNA interference techniques. Genomica, another subsidiary, provides molecular diagnostics for infectious diseases, including COVID-19 tests, and genetic analysis services in Spain. Pharma Mar, S.A. employs around 500 people and generates sales primarily from oncology products across regions like Europe, the United States, and China. In 2015, it absorbed Zeltia via reverse merger, streamlining operations and enhancing its position in marine-derived pharmaceuticals. Key figures include CEO José María Fernández de Sousa-Faro. As a leader in innovative marine biotechnology, it contributes significantly to global oncology treatments.